Caliper Life Sciences, Inc. (Nasdaq: CALP), a leading provider of tools and services for drug discovery, life sciences research and molecular diagnostics, today announced it has installed the 1000th IVIS preclinical imaging system, a milestone event in the continued rapid adoption of Caliper's proprietary in vivo imaging solutions.
The Center for Advanced Molecular Imaging at Northwestern University purchased Caliper's IVIS Spectrum to enable nano-particle technology research for the targeting of cancer tumors and non-invasive monitoring of tumor progression and therapeutic response in living subjects.
Caliper's IVIS imaging technology is the leading tool in the rapidly growing field of preclinical non-invasive optical molecular imaging. The technology provides researchers with novel capabilities to explore the molecular basis of disease and response to drug therapies in individual animal models over time-course studies without the need for invasive procedures maintaining the relevancy of biological model at hand. The use of IVIS technology has assisted in the discovery and development of at least 13 compounds that have moved into clinical testing, 5 of which are FDA approved treatments, and in the generation of more than 2,650 peer-reviewed publications, attesting to the value of IVIS technology in a broad range of therapeutic areas, including biomarker discovery, cancer research, stem cells, infectious disease, inflammation, metabolic disease, neurology, cardiovascular disease and toxicology.
"The Center for Advanced Molecular Imaging at Northwestern facilitates research fueling a greater understanding of disease and treatment options, so it is critical that the Center offer the University research community reliable technology solutions that are innovative and fundamentally enabling. The IVIS Spectrum provides an unparalleled combination of bioluminescence and fluorescence optical capabilities in a single, state-of-the-art instrument," said Dr. Thomas Meade, Director of the Center for Advanced Molecular Imaging (CAMI) in the Chemistry of Life Processes Institute at Northwestern University, Evanston Campus.
"Caliper's preclinical imaging solutions have gained rapid acceptance throughout the pharmaceutical and academic research communities. Researchers around the world rely on IVIS to provide meaningful, impactful molecular insights that simply could not be achieved through conventional means," said Kevin Hrusovsky, President and Chief Executive Officer of Caliper. "Placing the 1000th IVIS system at a prestigious institution such as Northwestern University is a testament to Caliper's partnership within the research community and our ability to commercialize leading-edge technology in strong collaboration with them. As evidenced by our recent acquisition of CRi, which adds multiplexed tissue analysis to our portfolio, we are continuing to invest in building out our vision of being the premier platform partner to enable personalized medicine."